Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ORCL has recovered 5% this week to $144.77, yet the stock remains down roughly 25% year-to-date, leaving the week's bounce looking more like a pause than a reversal.
The short-side picture has quietly shifted since the September 30 note. Short interest has retreated 1.2% over the week to 48.3 million shares, or 1.7% of the free float, reversing the 13.4% weekly build that was the headline of that prior note. The pullback in positioning is small in absolute terms, and the borrow market remains completely unencumbered: availability is at its maximum reading, with more than 2.3 billion shares available to lend, making new short positions trivially cheap to establish. Cost to borrow confirms it, falling 53% on the week to just 0.29%, its lowest level in months after a brief spike earlier in October. Options sentiment is similarly relaxed. The put/call ratio is 0.873, sitting less than half a standard deviation above its 20-day average of 0.856 and well below the 52-week high of 1.06. The setup is not charged in either direction: shorts are not pressing aggressively, and options traders are not paying up for downside protection.
The Street remains constructive in aggregate, with 26 buy ratings and a consensus of "buy," but the gap between analyst conviction and the stock price is hard to ignore. Most targets filed after the September 10 earnings print cluster in the $200 to $252 range, which implies roughly 40% to 74% upside from current levels. That gap reflects the size of the post-earnings drop: the stock fell 7% the day after the last print and lost nearly 7% over the following five days. Even the more bullish analysts, including UBS who nudged their target to $250 and Barclays to $252, have not been rewarded since. At the other end, RBC holds a Sector Perform rating with a $165 target, the most cautious on the register. On valuation, the trailing PE has eased to 14x and EV/EBITDA to 8.4x, both down meaningfully over the past 30 days as the price has fallen faster than earnings estimates. Factor scores show earnings momentum as a relative strength, with the 30-day EPS momentum rank at 76 and days-to-cover rank at 80, though the 12-month forward earnings growth rank sits at just 27, suggesting the Street's near-term optimism is not yet showing up in longer-horizon estimates.
The bull case rests on the AI infrastructure ramp. Cloud revenue grew 41% year-over-year to $8.9 billion in the most recent quarter, with AI-related demand reportedly up 243%. Remaining performance obligations jumped 325%, and management raised full-year revenue guidance to $90 billion. Bears counter that the valuation still prices in execution that has yet to materialise at the stock level, and that competition in databases and middleware remains intense. Oracle's high international exposure adds a foreign exchange variable that is difficult to hedge precisely. The ORTEX short score of 30.7 is stable and not flashing alarm, consistent with a name that is under pressure for fundamental reasons rather than positioning ones.
One insider data point is worth noting. Director Stephen Rusckowski purchased 25,000 shares in the open market on September 29 for approximately $3.5 million, with no 10b5-1 plan attached. That is a discretionary buy made near the lows of the recent selloff. Against that, the CEO filed tax-withholding transactions under a pre-arranged plan, which carry little signal. The net 90-day insider flow is a marginal $1.9 million on the sell side, so Rusckowski's purchase is the only unambiguous conviction signal in the register.
The next earnings event is November 18. Given that the last two prints produced moves of minus 7% on the day and plus 5.5% respectively, the question heading into that date is whether the AI revenue trajectory can narrow the gap between the Street's price targets and where the stock is actually trading.
See the live data behind this article on ORTEX.
Open ORCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
